Dr. Kasper on Imatinib Versus Sorafenib in Sarcoma
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.
There are 4 studies which used imatinib, explains Kasper. The most positive results from those studies demonstrate a treatment duration of 2 years and an overall response rate of 90%.
There is a retrospective study with sorafenib (Nexavar), which determined an overall response rate of 80% but demonstrated more toxicities than imatinib for patients being treated with sarcoma.